Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June
This article was originally published in The Pink Sheet Daily
Executive Summary
Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.